<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To understand how to appropriately recognize and manage <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> with iron chelation therapy (ICT) in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), evaluation of the role of different agents available for management of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, including efficacy, safety, and economic considerations for transfusion-dependent patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, is provided </plain></SENT>
<SENT sid="1" pm="."><plain>SUMMARY: Patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> have a high incidence of <z:hpo ids='HP_0001903'>anemia</z:hpo>, which often requires treatment </plain></SENT>
<SENT sid="2" pm="."><plain>Supportive care measures such as red blood cell transfusions and erythroid colony stimulating factors are mainstays of therapy </plain></SENT>
<SENT sid="3" pm="."><plain>Use of long-term transfusion therapy has limitations in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> due to the risk of developing <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Strategies to manage <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> include phlebotomy and ICT with agents such as <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> and <z:chebi fb="0" ids="49005">deferasirox</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>Data evaluating pharmacologic therapy for treatment of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> suggest timely intervention can mitigate the morbidity associated with this clinical syndrome </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSION: Development of practical management strategies to implement and optimize ICT using <z:chebi fb="0" ids="4356">deferoxamine</z:chebi> and <z:chebi fb="0" ids="49005">deferasirox</z:chebi> will be important to provide optimal care for transfusion-dependent patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>